Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data ArriVent BioPharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Research and development
64.9
79
153
General and administrative
9.71
15.3
24.2
Operating expenses
74.6
94.3
178
Operating income
-74.6
-94.3
-178
Net income
-69.3
-80.5
-166
EBITDA
-181
EPS, basic
-32.38
-2.56
-4.32
EPS, diluted
-32.38
-2.56
-4.32
Shares, basic (weighted)
2.14
31.5
38.5
Shares, diluted (weighted)
2.14
31.5
38.5
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
150
74.3
45.5
Short-term investments
145
267
Other current assets
9.58
8.12
20.1
Total current assets
160
227
333
Lease right-of-use assets
0.29
0.15
0.01
Long-term investments
47.7
Other non-current assets
0.11
0.13
0.19
Total assets
163
275
333
Accounts payable
4.53
3.78
5.93
Accrued liabilities
6.95
13.3
20
Total current liabilities
11.6
17.3
25.9
Lease liabilities
0.18
0.01
Total liabilities
11.8
17.3
25.9
Paid-in capital
4.65
496
712
Retained earnings
-158
-238
-405
Other comprehensive income
-0.21
0.01
Shareholders' equity
-153
258
307
Total equity
-153
258
307
Total liabilities and equity
163
275
333
Shares outstanding
2.75
33.7
42.5
Cash flow statement
FY2024
FY2024
FY2025
Net income
-69.3
-80.5
-166
Depreciation and amortization
-3.03
Stock-based compensation
0.9
3.21
12.5
Cash from operations
-55.8
-70.2
-161
Purchases of investments
-25
-194
-273
Sales and maturities of investments
1.7
202
Cash from investing
-192
-71.2
Stock issued
0.35
186
203
Cash from financing
42.9
187
203
Net change in cash
-13
-76.1
-28.8
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $28.45 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-44.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-41.5%
Net income / average total assets.
Return on invested capital (ROIC)
-65.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
19.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
21.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
22.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
14.2x
Current assets / current liabilities.
Quick ratio
13.4x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.4x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$3.11
Cash from operations / diluted weighted shares.
Book value per share
$7.59
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
3.82x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.82x
Market cap / tangible book value, when positive.
Earnings yield
-11.7%
Net income / market cap (the inverse of P/E).
Was ArriVent BioPharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $166.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.